1. A phase II randomized placebo‐controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance. Issue 1 (23rd October 2020) Authors: Jarrard, David; Filon, Mikolaj; Huang, Wei; Havighurst, Tom; DeShong, Katina; Kim, KyungMann; Konety, Badrinath R.; Saltzstein, Daniel; Mukhtar, Hasan; Wollmer, Barbara; Suen, Chen; House, Margaret G.; Parnes, Howard L.; Bailey, Howard H. Journal: Prostate Issue: Volume 81:Issue 1(2021) Page Start: 41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. (April 2014) Authors: Shore, Neal; Concepcion, Raoul; Saltzstein, Daniel; Lucia, M. Scott; van Breda, Arletta; Welbourn, William; Lewine, Nicolas; Gustavsen, Gary; Pothier, Kristin; Brawer, Michael K. Journal: Current medical research and opinion Issue: Volume 30:Number 4(2014:Apr.) Page Start: 547 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. (April 2014) Authors: Shore, Neal; Concepcion, Raoul; Saltzstein, Daniel; Lucia, M. Scott; van Breda, Arletta; Welbourn, William; Lewine, Nicolas; Gustavsen, Gary; Pothier, Kristin; Brawer, Michael K. Journal: Current medical research and opinion Issue: Volume 30:Number 4(2014:Apr.) Page Start: 547 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting. Issue 1 (April 2018) Authors: White, Jay; Shenoy, B.; Tutrone, Ronald; Karsh, Lawrence; Saltzstein, Daniel; Harmon, William; Broyles, Dennis; Roddy, Tamra; Lofaro, Lori; Paoli, Carly; Denham, Dwight; Reynolds, Mark Journal: Prostate cancer and prostatic diseases Issue: Volume 21:Issue 1(2018) Page Start: 78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. MP27-15 SABIZABULIN HAS BOTH CYTOTOXIC AND CYTOSTATIC ACTIVITY IN PHASE 1B/2 CLINICAL OF MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER WHO PROGRESSED ON ANDROGEN RECEPTOR TARGETING AGENTS. (May 2022) Authors: Markowski, Mark; Eisenberger, Mario; Pieczonka, Christopher; Getzenberg, Robert; Rodriguez, Domingo; Barnette, K. Gary; Steiner, MItchell; Saltzstein, Daniel; Antonarakis, Emmanuel; Tutrone, Ronald Journal: Journal of urology Issue: Volume 207(2022)Supplement 5 Page Start: e456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines. Issue 6 (4th March 2020) Authors: Shore, Neal D.; Antonarakis, Emmanuel S.; Cookson, Michael S.; Crawford, E. David; Morgans, Alicia K.; Albala, David M.; Hafron, Jason; Harris, Richard G.; Saltzstein, Daniel; Brown, Gordon A.; Henderson, Jonathan; Lowentritt, Benjamin; Spier, Jeffrey M.; Concepcion, Raoul Journal: Prostate Issue: Volume 80:Issue 6(2020) Page Start: 527 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects. Issue 2 (February 2018) Authors: Saltzstein, Daniel; Shore, Neal D.; Moul, Judd W.; Chu, Franklin; Concepcion, Raoul; de la Motte, Stephan; McLane, John A.; Atkinson, Stuart; Yang, Alex; Crawford, E. David Journal: Therapeutic advances in urology Issue: Volume 10:Issue 2(2018) Page Start: 43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Polymer‐delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open‐label studies in patients with advanced prostate cancer. (16th April 2016) Authors: Shore, Neal D.; Chu, Franklin; Moul, Judd; Saltzstein, Daniel; Concepcion, Raoul; McLane, John A.; Atkinson, Stuart; Yang, Alex; Crawford, E. David Journal: BJU international Issue: Volume 119:Number 2(2017) Page Start: 239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial. Issue 1 (26th January 2022) Authors: Chevli, K. Kent; Shore, Neal D.; Trainer, Andrew; Smith, Angela B.; Saltzstein, Daniel; Ehrlich, Yaron; Raman, Jay D.; Friedman, Boris; D'Anna, Richard; Morris, David; Hu, Brian; Tyson, Mark; Sankin, Alexander; Kates, Max; Linehan, Jennifer; Scherr, Douglas; Kester, Steven; Verni, Michael; Chamie... Journal: Journal of urology Issue: Volume 207:Issue 1(2022) Page Start: 61 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗